Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15568840 | 0.86 | PTGS2 (0.39) | TSHRMAPK14KDM4EL3MBTL1ALOX15 | |
| SCHEMBL15011653 | 0.75 | PRKCZ (0.48) | TSHRMAPK14ALOX15ALDH1A1PRKCZ | |
| SCHEMBL15011778 | 0.75 | PRKCZ (0.40) | TSHRMAPK14ALDH1A1TDP1PRKCZ | |
| SCHEMBL28740034 | 0.70 | ALDH1A1 (0.42) | TSHRKDM4EL3MBTL1ALDH1A1TDP1 | |
| SCHEMBL16739280 | 0.69 | SMN1; SMN2 (0.41) | MAPK14KDM4EL3MBTL1ALDH1A1MAPT | |
| SCHEMBL316526 | 0.67 | KDM4E (0.34) | KDM4E | |
| SCHEMBL536133 | 0.67 | PTGS1 (0.44) | TSHRKDM4EALDH1A1MAPTNPC1 | |
| SCHEMBL2958750 | 0.66 | — | — | |
| SCHEMBL1695877 | 0.65 | NOTUM (0.46) | CDK8TSHRMAPK14KDM4EALDH1A1 | |
| SCHEMBL9910542 | 0.64 | CDK8 (0.55) | CDK8MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111777592-B | N4- (2, 5-dimethoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof | 温州医科大学 | 2021-06-18 | — | — | CN | claimed |
| US-7928227-B2 | Diaryl ureas, which release urea compound when administered to patient, for example, 1-(4-chloro-3(trifluoromethyl)phenyl)-3-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)-2-oxo-(1,3,5-perhydrotriazapine); treatment of cancer, inflammation | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | claimed |
| EP-1599466-B1 | 2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATRORY DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-11-24 | — | — | EP | claimed |
| EP-1200411-B1 | PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (US) | 2005-12-14 | — | — | EP | claimed |
| US-20050032798-A1 | 2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders | BAYER HEALTHCARE LLC | 2005-02-10 | — | — | US | claimed |
| EP-4313293-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157300-A | Tetrahydrothienopyridine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-12-01 | — | — | CN | disclosed |
| US-8202899-B2 | Pyrazole urea derivatives used as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-1981851-B1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8044083-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8039639-B2 | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-6835832-B2 | Catalytic hydrogenation | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-6774233-B2 | AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-6753426-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030181718-A1 | A chemical intermediate carbamate compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | US | disclosed |
| US-20030166931-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | US | disclosed |
| US-6583282-B1 | Formation of a urea by reacting an aromatic carbamate with a aromatic amine | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-24 | — | — | US | disclosed |
| US-20030109703-A1 | Polymorph and process for preparing same | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181718-A1 | A chemical intermediate carbamate compounds | UGT1A1, ARG1, CPS1 | CDK8 950/4885TSHR 2875/4885MAPK14 4040/4885 |
| US-20030166931-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | URB2, UGT1A1, PURB | CDK8 1239/4885TSHR 3599/4885MAPK14 3398/4885 |
| US-20030109703-A1 | Polymorph and process for preparing same | UGT1A1, CYP1A1, CYP1B1 | CDK8 1705/4885TSHR 3513/4885MAPK14 4252/4885 |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | URB2, UGT1A1, PURB | CDK8 1239/4885TSHR 3599/4885MAPK14 3398/4885 |
| US-20050032798-A1 | 2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders | HYOU1, HIF1A, HCAR2 | CDK8 671/4885TSHR 4505/4885MAPK14 2817/4885 |
| US-20110124878-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | MAP3K19, MAP3K2, MAP3K20 | CDK8 189/4885TSHR 2615/4885MAPK14 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.